Evidence map›Paper›PMID 40529829›Full record

SynthesisFrontiers in endocrinology2025

Safety and efficacy of adjuvant Sotagliflozin therapy in patients with T1D - an update and systematic review and meta-analysis.

Yunzhen Lei, Shanshan Yao, Zhenglong Wang, Qianxian Tu, Zhengqiang Yuan, Qianfeng Jiang

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yunzhen Lei *Department of Clinical Medicine, Zunyi Medical University, Zunyi, Guizhou, China.
Shanshan Yao *Department of Cardiovascular Medicine, The Third Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Zhenglong WangDepartment of Cardiovascular Medicine, The Third Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Qianxian TuDepartment of Cardiovascular Medicine, The Third Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Zhengqiang YuanDepartment of Cardiovascular Medicine, The Third Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Qianfeng JiangDepartment of Clinical Medicine, Zunyi Medical University, Zunyi, Guizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This meta-analysis aims to assess the safety and efficacy of Sotagliflozin in patients with type 1 diabetes (T1D). Methods: Data on target organ protection, blood glucose levels, blood pressure, weight, insulin usage, and adverse events (AEs) associated with Sotagliflozin in the treatment of T1D were collected from databases including PubMed, Scopus, Web of Science, Embase, and the Cochrane Library. The search period extended until February 21, 2024, and included studies were restricted to randomized controlled trials (RCTs) investigating Sotagliflozin for T1D. The meta-analysis was performed using Stata 14 and RevMan 5.4. Results: A total of 12 randomized controlled trials were included in the analysis, with treatment durations ranging from 14 to 52 weeks. Sotagliflozin, when used in combination with insulin therapy, resulted in significant reductions in cardiovascular disease (CVD) risk (-6.38%; Conclusion: In T1D patients, Sotagliflozin adjunct therapy improves blood glycemia, stabilizes blood pressure, and reduces cardiovascular risk factors. It also shows potential in lowering fracture risk, but the risk of DKA requires further clinical validation. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/#joinuppage, identifier CRD42023467427.

Indexed as

Diabetes Mellitus, Type 1GlycosidesHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsBlood GlucoseHumansRandomized Controlled Trials as TopicTreatment Outcome(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triolBlood GlucoseGlycosidesHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitorsmeta-analysisSGLT1SGLT2Sotagliflozintype 1 diabetes

Identifiers

PMID40529829
PMCPMC12170572

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.